Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM Pharmaceutical Products has announced that its new cGMP custom biopharmaceutical manufacturing plant in Brisbane, Australia, will open in June this year.
Subscribe to our email newsletter
The DSM plant was built with the cooperation of the Queensland and Commonwealth Governments of Australia.
DSM Biologics president Karen King said that the company’s partnership with the Government of Queensland and the Commonwealth of Australia has led to the addition to the Australian biotechnology industry.
The DSM operation will provide cGMP mammalian cell-culture contract manufacturing services from process development through to commercial manufacturing.
DSM Biologics, which operates with standard technologies, also has a portfolio of technologies for the optimization of biopharmaceutical manufacturing, reducing the cost and risk of mammalian cell culture.
The facility has an annual output capability of 500kg and has expansion space available for further capacity utilization.
BioPharmaceuticals Australia CEO David Hughes said, "The opening of this facility satisfies a national capability gap. Our partnership gives Australia and the wider region access to DSM’s extensive experience, expertise and ongoing commitment to developing improved bioprocessing technologies."
Image : DSM Biologics Brisbane (center) adjacent to the Translational Research Institute of Queensland. Photo: Courtesy of B3C newswire.